Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer

Introduction: Mirvetuximab soravtansine (MIRV) recently emerged as a promising therapeutic option for patients with platinum resistant ovarian cancer (PROC). In trials leading up to its approval, several ocular and other toxicities were identified. We report our experience with MIRV in a less-select...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Susan M. Lang, Filippos Vingopoulos, Isabel Beshar, Sahana Somasegar, Elizabeth V. Adams, Simone A. Sasse, Talayeh Ghezelayagh, Emily Clair McClung, Amer Karam, Oliver Dorigo, Prithvi Mruthyunjaya, Babak Litkouhi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-06-01
coleção:	Gynecologic Oncology Reports
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2352578925000633
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!